Concepedia

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

Anne Katrin Sjølie, Ronald Klein, Massimo Porta, Trevor J. Orchard, John Fuller, Hans Henrik Parving, Rudy Bilous, Nish Chaturvedi

The Lancet · 2008 · 432 citations · 46 references

DOI

Concepts

References

46

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 20.1K citations

, , +13

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

, , +15

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw et al. · New England Journal of Medicine · 2001 · 7.5K citations · Full text

, , +17

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

BMJ · 1998 · 6.7K citations · Full text

, , +16

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke et al. · New England Journal of Medicine · 2001 · 6K citations · Full text

, , +16